Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning InMode business and prospects, resulting in its stock trading at inflated prices.

INDM INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of InMode Ltd. (“InMode” or the “Company”) (NASDAQ: INMD) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 17, 2023, an investigative publication reported that InMode had threatened some customers with legal action over complaints made regarding the Company's devices and sales.

The Law Offices of Frank R. Cruz Announces Investigation of InMode Ltd.

NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit in the U.S. District Court for the Central District of California alleging violations of the federal securities laws by InMode Ltd. (“InMode” or the “Company”) and certain of the Company's senior executives (collectively, “Defendants”). The action is brought on behalf of all persons or entities that purchased or otherwise acquired InMode c.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against InMode Ltd.

InMode stock skidded Tuesday as high interest rates weighed on the aesthetics company's sales. Shares fell to a floor near their 50-day line.

Former Highflier InMode Crumbles As Interest Rates, Macro Weigh On Aesthetics Procedures

InMode Ltd. (INMD) Q4 2023 Earnings Call Transcript

YOKNEAM, Israel, Feb. 13, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023.

InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M

Transmedics Group Inc

Top stocks keep driving the major market indexes to new heights, but some quality businesses aren't getting the attention they deserve. TransMedics Group is cornering the market for handling organs for transplant.

Forget the "Magnificent Seven": These 2 Under-the-Radar Growth Stocks Are Better Bargains

InMode (INMD) closed at $23.55 in the latest trading session, marking a -1.88% move from the prior day.

Here's Why InMode (INMD) Fell More Than Broader Market

InMode stock has consolidated constructively but has not experienced the renewed enthusiasm observed in other med tech stocks. Near-term headwinds are expected to persist for INMD due to its specialization in aesthetics. Management offered tepid guidance for 2024. INMD's guidance aligns with caution from Baird, pointing to challenges in the aesthetics market that are expected to persist for at least another fiscal year.

InMode: Take The Plunge Before It Goes Into Beast Mode

In the closing of the recent trading day, InMode (INMD) stood at $24.03, denoting a -0.99% change from the preceding trading day.

InMode (INMD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, InMode (INMD) closed at $22.72, marking a -1.17% move from the previous day.

InMode (INMD) Stock Declines While Market Improves: Some Information for Investors

InMode's stock valuation has fluctuated over time, with high multiples in 2021 due to impressive growth. The company's growth has since slowed down as it has matured.

InMode: Good Margin Of Safety At Current Levels

In the closing of the recent trading day, InMode (INMD) stood at $21.88, denoting a +1.44% change from the preceding trading day.

InMode (INMD) Rises As Market Takes a Dip: Key Facts

Conference call to be held on Tuesday, February 13, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 16, 2024 /PRNewswire/ -- InMode Ltd.

InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M

In the most recent trading session, InMode (INMD) closed at $21.37, indicating a +1.96% shift from the previous trading day.

InMode (INMD) Outperforms Broader Market: What You Need to Know

In the closing of the recent trading day, InMode (INMD) stood at $21.01, denoting a +0.05% change from the preceding trading day.

InMode (INMD) Advances While Market Declines: Some Information for Investors

InMode has a depressed valuation with a forward P/E of 8.70 in 2024. The company is facing challenges with falling revenue and EBITDA, despite being highly profitable. The weakening of Covid pent-up demand adds an interesting layer to the investment landscape.

InMode: Despite Attractive Valuation, I Believe It's Premature To Dive In - Here's Why

INMD continues to report robust consumable sales, with the downgraded FY2023 top-line guidance only attributed to the elevated interest rate environment.

InMode Is Inherently Undervalued - Bullish Support Observed

The latest trading day saw InMode (INMD) settling at $22.54, representing a +0.18% change from its previous close.

InMode (INMD) Exceeds Market Returns: Some Facts to Consider

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of InMode Ltd. ("InMode" or the "Company") (NASDAQ: INMD).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On InMode Ltd.- INMD

Inmode Ltd shares slid more than 12% in pre-market trading on Wednesday after the medical tech company reduced its full-year 2023 guidance, due primarily to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales.  Inmode said it now expects adjusted earnings per share (EPS) for the year of $2.47 to $2.50, down from previous guidance of $2.53 to $2.57.

Inmode stock drops on sales, profit warning

The stock of InMode Ltd. INMD, -4.33%, an Israeli medical tech company, fell 13% early Wednesday, after the company cut its full-year guidance to reflect stronger-than-expected headwinds from the current macro environment, that was causing a slowdown in platform sales, mainly in North America.

InMode's stock slides 13% after Israeli medtech company issues profit warning

YOKNEAM, Israel , Dec. 6, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it is revising its full-year 2023 guidance.

InMode Revises Full-Year 2023 Guidance

Bitfarms Ltd

InMode is a medical device company that could benefit from more weight-loss treatments entering the market. Bitfarms has been having a great year due to the rising popularity of crypto, and that trend could continue into 2024.

2 Small-Cap Stocks With Big Potential in 2024

Doximity

Battling significant decelerations in sales growth, both companies are cheaper than ever. One-sixth of Doximity's market capitalization comes from its large cash balance.

News for Inmode Ltd Stock (INMD)